Recurrent UTI prevention clinical trial – currently recruiting

Intravesical preparations for recurrent urinary tract infection prevention (the VESPER trial): a multi-arm, multi-site open label randomised superiority trial.

The VESPER trial is a Department of Health and Social Care funded clinical trial aimed at finding the best preventative treatment for women with recurrent urinary tract infections (UTIs).

The trial is sponsored by The Newcastle Upon Tyne NHS Foundation Trust and co-ordinated by the Centre for Trials Research at Cardiff University.

The VESPER trial aims to determine the relative clinical and cost-effectiveness of the two most commonly used intravesical preventative treatments for women who fail first-line preventative treatment for recurrent urinary tract infection (UTI) and compare this to standard second line oral antibiotic prophylaxis in a UK NHS setting to demonstrate treatment superiority in terms of UTI reduction rate.

You have received this information sheet because your patient has been made aware of this trial and is interested in taking part.

The eligibility criteria for the trial are:

Inclusion criteria:

- Women with recurrent uncomplicated UTI who have failed first-line treatments (at least three episodes of symptomatic antibiotic-treated urinary infection in the previous 12 months or two episodes of UTI in the last 6 months despite the use of first line treatments). Failed first-line treatments can include antibiotics, methenamine (antiseptic) or vaginal oestrogen.
- Women aged ≥16 years
- Women able to receive intravesical treatments and take second-line oral antibiotic prophylaxis
- Women able to give informed consent
- Women willing to adhere to a 12-month study protocol

Exclusion criteria:

- Women unable to receive intravesical treatments or second-line oral antibiotic prophylaxis
- Women with structural or functional urinary tract abnormalities considered contributory to rUTI
- Pregnancy or intended pregnancy in next 12 months
- Women who are breast feeding

* If a patient has symptoms of a UTI at time of the eligibility assessment and a subsequent urine culture test is positive they will be treated for the UTI and have a 4-week antibiotic wash-out period before being invited back to clinic to complete eligibility, consent and randomisation.

If you would ordinarily consider referring this patient, we would be grateful if you could instead refer them to a hospital site participating in the VESPER study (see link below). At the site, your patient will be provided with full details of the trial and, if eligible, will be invited to take part.

You can find out more about the VESPER trial by following the link below. Here you will find a list of the participating VESPER trial sites, the principal investigator (PI) name and their contact details to facilitate a referral to one of them.

When referring a patient please include on your standard referral form:

"This patient wants to be considered for the VESPER trial and therefore could this referral be passed directly to {PI name} who is the local principal investigator for the trial".

https://liveutifree.com/VESPER-trial

Yours sincerely,

Chief Investigator of the VESPER Trial

Professor Chris Harding

Consultant Urological Surgeon

The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Freeman Road

High Heaton

Newcastle upon Tyne

England

NE7 7DN

Tel : 01912137321

c.harding@nhs.net

If you require further information please contact the Centre for Trials Research, Cardiff University:

Trial Manager: Janine Bates: Vesper@cardiff.ac.uk

Tel: 02920687616